Rezultati

eNauka >  Results >  EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Title: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Authors: Rice, Andrew S C; Dworkin, Robert H; McCarthy, Tom D; Anand, Praveen; Bountra, Chas; McCloud, Philip I; Hill, Julie; Cutter, Gary; Kitson, Geoff; Desem, Nuket;
Raff, Milton;
Issue Date: 2014
Publication: The Lancet
ISSN: 0140-6736 Lancet Search Idenfier
Type: Article
Collation: vol. 383 br. 9929 str. 1637-1647
DOI: 10.1016/s0140-6736(13)62337-5
WoS-ID: 000335670800026
Scopus-ID: 2-s2.0-84900307488
URI: https://enauka.gov.rs/handle/123456789/307855
Metadata source: Migrirano iz RIS podataka
M-category: 
21a+M21a+

184
SCOPUSTM
137
OpenCitations
167
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.